Top

Improved Drug Susceptibility Testing (DST) for Mycobacteria

Active

Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The National Institute of Allergy and Infectious Diseases (NIAID), under the Department of Health and Human Services, is seeking to develop improved drug susceptibility tests (DSTs) for mycobacterial drugs. This initiative targets both tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections, focusing on current treatments, new drugs, and those in late-stage clinical development. The goal is to replace slow, culture-based processes with innovative rapid genotypic and improved phenotypic methods that do not require full culture growth, thereby enhancing treatment guidance and reducing drug-resistant transmission. This opportunity is listed as a forecast with the NAICS code 541715. It is authorized under the Public Health Service Act and relevant federal regulations to address the rising rates of NTM lung disease and the increase in drug-resistant TB strains. Interested parties can contact the NIAID Division of Microbiology and Infectious Diseases for further information.

General Info

Develop rapid drug susceptibility tests for TB and NTM pathogens using genotypic and phenotypic technologies without culture growth.

Agency

Department Of Health And Human Services → National Institutes Of Health

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PostedJun 24

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health

Contacts1 person available

OfficeUSA

Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health

Office AddressUSA

Contacts

NIAID DST (Division of Microbiology and Infectious Diseases

contact@example.gov

Full Description

The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting research to develop improved drug susceptibility tests (DSTs) for mycobacterial drugs, including those currently used for treatment of tuberculosis (TB) and clinically important non-tuberculous mycobacterial (NTM) infections, new drugs and drugs in late-stage clinical development. TB is a leading cause of death from an infectious disease worldwide and drug-resistant strains of TB, including those resistant to new drug regimens, are increasing. In the United States, rates of NTM lung disease are rising, especially among women and older adults, while TB cases have surged to their highest level in ten years. Current assays utilize slow, culture-based processes that do not allow for the rapid testing of mycobacterial strains and their drug susceptibility. Improved DSTs are essential for guiding effective treatment, reducing drug-resistant mycobacterial rates, and preventing new transmissions. This program will support the development of innovative DST assays, including rapid genotypic and improved phenotypic methods that do not require full culture growth. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.